Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 256-265 , October 2009

Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine

  • Albert Stuart Reece, M.B.B.S., F.R.A.C.G.P., F.R.C.S. (Ed.), F.R.C.S. (Glas.), M.D.

      Affiliations

    • Corresponding Author InformationSouthcity Family Medical Centre, 39 Gladstone Rd., Hillgate Hill, Queensland 4101, Australia. Tel.: +61 738444000; fax: +61 738444015.

Received 30 June 2008 ,Revised 8 February 2009 ,Accepted 2 March 2009.

References 

  1. Brugal MT, Domingo-Salvany A, et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005;100:981–989
  2. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol. 2006;1:280–295
  3. Canales JJ. Adult neurogenesis and the memories of drug addiction. European Archives of Psychiatry and Clinical Neuroscience. 2007;257:261–270
  4. Caplehorn JR, Dalton MS, et al. Methadone maintenance and addicts' risk of fatal heroin overdose. Substance Use & Misuse. 1996;31:177–196
  5. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved. The Medical Journal of Australia. 1999;170:104–109
  6. Carter EF. Dental implications of narcotic addiction. Australian Dental Journal. 1978;23:308–310
  7. Clausen T, Anchersen K, et al. Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug and Alcohol Dependence. 2008;94:151–157
  8. Comer SD, Sullivan MA, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry. 2006;63:210–218
  9. Darke S, Dagenhardt L, Mattick R. Mortality amongst illicit drug users: Epidemiology, causes and intervention. Sydney: Cambridge University Press; 2007;
  10. Davstad I, Stenbacka M, et al. An 18-year follow-up of patients admitted to methadone treatment for the first time. Journal of Addictive Diseases. 2009;28:39–52
  11. Degenhardt L, Gibson A, et al. Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev. 2008;27:1–3
  12. Desai RI, Neumeyer JL, et al. Behavioral effects of the R-(+)- and S-(−)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys. European Journal of Pharmacology. 2007;558:98–106
  13. Digiusto E, Shakeshaft A, et al. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99:450–460
  14. Drake CT, Chavkin C, et al. Opioid systems in the dentate gyrus. Progress in Brain Research. 2007;163:245–263
  15. Dunbar JL, Turncliff RZ, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcoholism, Clinical and Experimental Research. 2006;30:480–490
  16. Dunbar JL, Turncliff RZ, et al. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs. 2007;68:862–870
  17. Dyer KR, White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction. 1997;92:1445–1455
  18. Eisch AJ, Harburg GC. Opiates, psychostimulants, and adult hippocampal neurogenesis: Insights for addiction and stem cell biology. Hippocampus. 2006;16:271–286
  19. Fan J, Hser YI, et al. Tooth retention, tooth loss and use of dental care among long-term narcotics abusers. Journal of Substance Abuse. 2006;27:25–32
  20. Farrokhi CB, Tovote P, et al. Cortagine: Nehavioral and autonomic function of the selective CRF receptor subtype 1 agonist. CNS Drug Rev. 2007;13:423–443
  21. Franceschi C, Bonafe M, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences. 2000;908:244–254
  22. Galarneau DW, Teres JJ, et al. Antidepressant treatment patterns in a novel methadone maintenance clinic targeting young adults an observational study. Journal of Addictive Diseases. 2006;25:47–52
  23. Gibson A, Degenhardt L, et al. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103:462–468
  24. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35:192–213
  25. Gronbladh L, Ohlund LS, et al. Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatrica Scandinavica. 1990;82:223–227
  26. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: A controlled study. Drug Alcohol Depend. 1981;7:249–256
  27. Hamilton RJ, Olmedo RE, et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Academic Emergency Medicine. 2002;9:63–68
  28. Hser YI, Anglin D, et al. A 24-year follow-up of California narcotics addicts. Archives of General Psychiatry. 1993;50:577–584
  29. Hser YI, Hoffman V, et al. A 33-year follow-up of narcotics addicts. Archives of General Psychiatry. 2001;58:503–508
  30. Hulse GK, Arnold-Reed DE, Ngo H, Reece AS. Naltrexone implants in the treatment of heroin addiction. Trends in substance abuse research. M.C.R. New York, Nova. 2007;1:71–88
  31. Hulse GK, Low VH, et al. Biodegradability of naltrexone-poly(dl) lactide implants in vivo assessed under ultrasound in humans. Addiction Biology. 2007;
  32. Hulse GK, O'Neill G. A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2002;42:93–94
  33. Hulse GK, O'Neil G, et al. Use of oral and implantable naltrexone in the management of the opioid impaired physician. Anaesthesia and Intensive Care. 2003;31:196–201
  34. Hulse GK, O'Neil G, et al. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. International Journal Of Gynaecology And Obstetrics. 2004;85:170–171
  35. Hulse GK, Tait RJ, et al. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug and Alcohol Dependence. 2005;79:351–357
  36. Jeffrey GP, MacQuillan G, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology. 2007;45:111–117
  37. Johnson BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opinion on Pharmacotherapy. 2006;7:1065–1073
  38. Kim TW, Alford DP, et al. Low bone density in patients receiving methadone maintenance treatment. Drug and Alcohol Dependence. 2006;85:258–262
  39. Kolodziej A, Stumm R, et al. Endogenous opioids inhibit ischemia-induced generation of immature hippocampal neurons via the mu-opioid receptor. The European Journal of Neuroscience. 2008;27:1311–1319
  40. Kranzler HR, Wesson DR, et al. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcoholism, Clinical and Experimental Research. 2004;28:1051–1059
  41. Li Y, Wang X, et al. Methadone enhances human immunodeficiency virus infection of human immune cells. The Journal of Infectious Diseases. 2002;185:118–122
  42. Martelle JL, Claytor R, et al. Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxami de] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzami de], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics. 2007;321:573–582
  43. McCann DJ. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clinical Pharmacology and Therapeutics. 2008;83:627–630
  44. McCarthy L, Wetzel M, et al. Opioids, opioid receptors, and the immune response. Drug and Alcohol Dependence. 2001;62:111–123
  45. Miotto K, McCann M, et al. Naltrexone and dysphoria: Fact or myth?. The American Journal on Addictions. 2002;11:151–160
  46. Miotto K, McCann MJ, et al. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug and Alcohol Dependence. 1997;45:131–134
  47. Novick DM, Ochshorn M, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. The Journal of Pharmacology and Experimental Therapeutics. 1989;250:606–610
  48. O'Neil G, Hulse G, et al. Rapid opioid detoxification in Australia. Academic Emergency Medicine. 2002;9:960
  49. Ochshorn M, Bodner G, et al. The effect of methadone in vitro on natural killer (NK) activity. NIDA Research Monograph. 1989;95:522–523
  50. Pillai R, Nair BS, et al. AIDS, drugs of abuse and the immune system: A complex immunotoxicological network. Archives of Toxicology. 1991;65:609–617
  51. Reece AS. Dentition of addiction in Queensland: Poor dental status and major contributing drugs. Australian Dental Journal. 2007;52:144–149
  52. Reece AS. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immunity and Ageing,. 2007;4:6
  53. Reece AS. Hair graying in substance addiction. Archives of Dermatology. 2007;143:116–118
  54. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy. 2007;2:35–49
  55. Reece AS. Chronology and patterns of psychiatric morbidity in substance dependent and medical patients. Australasian Psychiatry. 2008;(In Press)
  56. Reece AS. Clinical implications of addiction related immunosuppression. The Journal of Infection. 2008;56:437–445
  57. Reece AS. Experience of road and other trauma by the opiate dependent patient. J Subst Abuse Treat Prev Policy. 2008;3:10–21
  58. Reece AS, Davidson P. Deficit of circulating stem—Progenitor cells in opiate addiction: A pilot study. Subst Abuse Treat Prev Policy. 2007;2:19
  59. Rock RB, Gekker G, et al. WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: Involvement of cannabinoid receptors. J Neuroimmune Pharmacol. 2007;2:178–183
  60. Schreiber S, Peles E, et al. Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients. Drug and Alcohol Dependence. 2008;92:79–85
  61. Sullivan LE, Metzger DS, et al. Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100:150–158
  62. Sullivan MA, Vosburg SK, et al. Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl). 2006;189:37–46
  63. Suzuki S, Carlos MP, et al. Methadone induces CCR5 and promotes AIDS virus infection. FEBS Letters. 2002;519:173–177
  64. Tait RJ, Ngo HT, et al. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. Journal of Substance Abuse Treatment. 2007;
  65. Tait RJ, Ngo HT, et al. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. Journal of Substance Abuse Treatment. 2008;35:116–124
  66. UNAIDS . 2006 Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS; 2007;
  67. Vasto S, Candore G, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mechanisms of Ageing and Development. 2007;128:83–91
  68. Ward J, Mattick RP, et al. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers; 1998;
  69. Wikler A. Methadone maintenance and narcotic blocking drugs. Appendix. Int J Addict. 1977;12:869–881
  70. Woody GE, Metzger D, et al. Psychiatric symptoms, risky behavior, and HIV infection. NIDA Research Monograph. 1997;172:156–170
  71. Zagon IS, Verderame MF, et al. The biology of the opioid growth factor receptor (OGFr). Brain Research. Brain Research Reviews. 2002;38:351–376

 Work was conducted at Southcity Family Medical Centre. This work is the work of ASR in its entirety.

 Conflicts of interest: Naltrexone implants were sold to some patients through this clinic for use in their treatment on campus.

PII: S0740-5472(09)00028-2

doi: 10.1016/j.jsat.2009.03.008

Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 256-265 , October 2009

Article Tools

* Image Usage & Resolution